Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > 88% demonstrate that CR at 180 days, 69% at 270 days

<< Previous

Bullboard Posts

Next >>

Comment by enriquesuaveon May 30, 2022 6:18pm

200 Views

Post# 34718327

RE:88% demonstrate that CR at 180 days, 69% at 270 days

Very good and steady data so far. Next read out will have more data at different time intervals. 270 days data should be telling IMHO

ScienceFirst wrote: 3 more patients treated since April 29.

Efficacy is still improving. Sounds like a Breakthrough designation winner and a future Standard of Care (SOC).

For all Evaluable Patients, who achieved a CR at 90 days, 88% demonstrate that CR at 180 days, 69% at 270 days, 50% at 360 days and 56% at 450 days, demonstrating a strong duration of complete response.